John Balser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Balser has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Harry Keyserling
Emory University Department of Pediatric Infectious Diseases, Atlanta, GA, USA
1 shared publication - John Jay Treanor
University of Rochester Medical Center
1 shared publication - Lisa A. Jackson
Group Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101, United States
1 shared publication - Louis Fries
GlaxoSmithKline Biologicals, Columbia, Maryland, USA
1 shared publication - Manjusha J. Gaglani
Section of Pediatric Infectious Diseases, Scott & White Memorial Hospital and Clinic, Texas A&M University Health Science Center College of Medicine, Temple, Texas, USA
1 shared publication - Nancy Bouveret
GlaxoSmithKline Biologicals, Laval, Québec, Canada
1 shared publication
Latest Publications
- Open Access
- 17 March 2010
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 10 (1) , 71
Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons
Seasonal influenza imposes a substantial personal morbidity and societal cost burden. Vaccination is the major strategy for influenza prevention; however, because antigenically drifted influenza A and B viruses circulate annually, influenza vaccines must be updated to provide protection against the predicted prevalent strains for the next influenza season. The aim of this study was to assess the efficacy, safety, reactogenicity, and immunogenicity of a trivalent inactivated split virion influenza vaccine (TIV) in healthy adults over two influenza seasons in the US.
- 17 March 2010
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 10 (1) , 71
Open AccessSafety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons
Seasonal influenza imposes a substantial personal morbidity and societal cost burden. Vaccination is the major strategy for influenza prevention; however, because antigenically drifted influenza A and B viruses circulate annually, influenza vaccines must be updated to provide protection against the predicted prevalent strains for the next influenza season. The aim of this study was to assess the efficacy, safety, reactogenicity, and immunogenicity of a trivalent inactivated split virion influenza vaccine (TIV) in healthy adults over two influenza seasons in the US.